Jerusalem Pharmaceuticals Co. Ltd. announced unaudited earnings results for the full year ended December 31, 2017. For the year, the company reported sales of $35,150,792 against $28,601,050 a year ago. Net income before tax was $6,287,361 against $3,230,008 a year ago. Net income after tax was $6,186,852 or $0.342 per basic and diluted share against $3,050,959 or $0.176 per basic and diluted share a year ago. Net cash flow from operating activities was $4,856,200 against $2,483,558 a year ago. Purchase of property, plant and equipment was $1,626,021 against $699,065 a year ago. Purchase of intangible assets was $305,234 against $207,657 a year ago.